Literature DB >> 24960211

Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.

Christophe Cassinotto1, Amaury Mouries, Jean-Pierre Lafourcade, Eric Terrebonne, Geneviève Belleannée, Jean-Frédéric Blanc, Bruno Lapuyade, Véronique Vendrely, Christophe Laurent, Laurence Chiche, Tristan Wagner, Antonio Sa-Cunha, Delphine Gaye, Hervé Trillaud, François Laurent, Michel Montaudon.   

Abstract

PURPOSE: To prospectively evaluate the utility of computed tomography (CT) for determination of tumor response and prediction of resectability after neoadjuvant combined chemotherapy and radiation therapy (CRT) in patients with nonmetastatic locally advanced pancreatic cancer.
MATERIALS AND METHODS: This study received institutional review board approval, and all participants provided written informed consent. Consecutive patients with cephalic locally advanced pancreatic cancer who underwent surgical exploration and/or resection following neoadjuvant CRT were prospectively enrolled from June 2009 to May 2013. Two radiologists independently analyzed the baseline and post-CRT CT scans for the size, attenuation, and circumferential vascular contacts of the tumor. Associations between the postoperative histologic grade of the tumor response (pTNM) and the clinical, biologic, and CT criteria were assessed by using Spearman correlation coefficients. CT criteria related to the presence of complete (ie, R0) resection were assessed by using logistic regression.
RESULTS: Forty-seven patients were included, 33 with an R0 resection and 14 with positive margins (ie, R1) or no resection. Variables demonstrating a significant correlation with the histologic tumor classification of tumor response were post-CRT carbohydrate antigen 19-9 level (r = 0.46), post-CRT largest tumor axis (r = 0.44), post-CRT sum of the largest and smallest tumor axes (r = 0.46), change in the largest axis (r = -0.31), change in the sum of the largest and smallest axes (r = -0.39), change in superior mesenteric vein (SMV) and/or portal vein (hereafter, SMV/portal vein) contact (r = -0.38), and post-CRT superior mesenteric artery contact (r = 0.34). Partial regression of tumor contact with the SMV/portal vein was associated in all cases with R0 resection (10 of 10 patients, positive predictive value = 100%), and partial regression of tumor contact with any peripancreatic vascular axis was associated with R0 resection in 91% of cases (20 of 22 patients, positive predictive value = 91%). Persistence of SMV/portal vein stenosis after CRT was not predictive of R1 resection.
CONCLUSION: Partial regression of tumor-vessel contact indicates suitability for surgical exploration, irrespective of the degree of decrease in tumor size or the degree of residual vascular involvement. © RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24960211     DOI: 10.1148/radiol.14132914

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  26 in total

Review 1.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

2.  Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?

Authors:  Laurent Sulpice; Olivier Turrini; Jonathan Garnier; Fabien Robin; Jacques Ewald; Ugo Marchese; Damien Bergeat; Karim Boudjema; Jean-Robert Delpero
Journal:  Ann Surg Oncol       Date:  2021-01-18       Impact factor: 5.344

3.  CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.

Authors:  Mathilde Wagner; Celia Antunes; Daniel Pietrasz; Christophe Cassinotto; Magaly Zappa; Antonio Sa Cunha; Oliver Lucidarme; Jean-Baptiste Bachet
Journal:  Eur Radiol       Date:  2016-11-28       Impact factor: 5.315

4.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

5.  Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.

Authors:  Giovanni Marchegiani; Valentina Todaro; Enrico Boninsegna; Riccardo Negrelli; Binit Sureka; Debora Bonamini; Roberto Salvia; Riccardo Manfredi; Roberto Pozzi Mucelli; Claudio Bassi
Journal:  Eur Radiol       Date:  2018-04-20       Impact factor: 5.315

Review 6.  Use of imaging as staging and surgical planning for pancreatic surgery.

Authors:  Andrew Hieu Nguyen; Laleh G Melstrom
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

7.  CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.

Authors:  Bo Ram Kim; Jung Hoon Kim; Su Joa Ahn; Ijin Joo; Seo-Youn Choi; Sang Joon Park; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-06-21       Impact factor: 5.315

Review 8.  Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

Review 9.  Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.

Authors:  Elena Gabriela Chiorean; Andrew L Coveler
Journal:  Drug Des Devel Ther       Date:  2015-07-07       Impact factor: 4.162

Review 10.  Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.

Authors:  Yun Zhang; Zi-Xing Huang; Bin Song
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.